Impact of anemia on short‐term outcomes after TAVR: A subgroup analysis from the BRAVO‐3 randomized trial
Catheterization and Cardiovascular Interventions2021Vol. 98(6), pp. E870–E880
Citations Over Time
Victor Razuk, Anton Camaj, Davide Cao, Johny Nicolas, Christian Hengstenberg, Samantha Sartori, Zhongjie Zhang, David Power, Frans Beerkens, Mauro Chiarito, Nicolas Méneveau, Christophe Tron, Nicolas Dumonteil, Julian D. Widder, Markus Ferrari, Roberto Violini, Pieter R. Stella, Raban Jeger, Prodromos Anthopoulos, Roxana Mehran, George Dangas
Abstract
Anemia was not associated with a higher risk of NACE or major bleeding at 30 days after TAVR without modification of the treatment effects of periprocedural anticoagulation with bivalirudin versus UFH.
Related Papers
- Successful multi-vessel percutaneous coronary intervention with bivalirudin in a patient with severe hemophilia A: a case report and review of literature.(2004)
- → Combined Use of Bivalirudin and Radial Access in Acute Coronary Syndromes Is Not Superior to the Use of Either One Separately(2016)24 cited
- → Bivalirudin versus heparin and provisional GP IIb/IIIa inhibitors in patients treated for ST‐segment elevation myocardial infarctions: Comparison of outcomes in a “real‐world” setting(2017)5 cited
- → Heparin, bivalirudin, or the best of both for STEMI interventions(2019)3 cited
- Bivalirudin in the cardiac cath lab: streamlining the percutaneous coronary intervention experience.(2004)